By Kevin E. Noonan — The Federal Circuit exhibited the current status of its obviousness jurisprudence in affirming the District Court’s determination that the asserted claims of U.S. Patent No. 8,410,131 were obvious in a decision handed down this week in Novartis Pharmaceuticals Corp. v. West-Ward Pharmaceuticals Int’l. The case arose in ANDA litigation over Novartis’s Afinitor product (everolimus, a rapamycin derivative; the structure of this compound is set out in claim 1 of the ‘131 patent) to treat renal cell carcinoma (RCC), a particularly resistant form of cancer. Novartis asserted claims 1-3 of the ‘131 patent, directed to methods…
View the original article here: Novartis Pharmaceuticals Corp. v. West-Ward Pharmaceuticals Int’l (Fed. Cir. 2019)
The article was originally posted on Patent Docs.
Each article is copyrighted to their original authors. We do not own any rights to the news or the images used. Whilst every care is taken to ensure that the news posts published are accurate, we cannot guarantee the authenticity of the news article on every occasion. There’s no copyright infringement intended. The news is for informational purposes only and does not provide legal advice.